Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43866   clinical trials with a EudraCT protocol, of which   7287   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-003065-15
    Sponsor's Protocol Code Number:WO29519
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2021-02-08
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2014-003065-15
    A.3Full title of the trial
    A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE III STUDY OF IDASANUTLIN, AN MDM2 ANTAGONIST, WITH CYTARABINE VERSUS CYTARABINE PLUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
    STUDIO DI FASE III MULTICENTRICO, IN DOPPIO CIECO, RANDOMIZZATO, CONTROLLATO CON PLACEBO, SULL¿USO DI IDASANUTLIN, UN ANTAGONISTA DI MDM2, ASSOCIATO A CITARABINA RISPETTO A CITARABINA PI¿ PLACEBO IN PAZIENTI AFFETTI DA LEUCEMIA MIELOIDE ACUTA (LMA) RECIDIVATA O REFRATTARIA
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study of Idasanutlin with Cytarabine versus Cytarabine plus Placebo in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
    Studio con Idasanutlin associato a Citarabina rispetto a Citarabina pi¿ Placebo in pazienti affetti da Leucemia Mieloide Acuta Recidivata o Refrattaria
    A.3.2Name or abbreviated title of the trial where available
    -
    Studio con Idasanutlin associato a Citarabina rispetto a Citarabina più Placebo in pazienti affetti
    A.4.1Sponsor's protocol code numberWO29519
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT02545283
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorF. HOFFMANN - LA ROCHE LTD.
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportF. Hoffmann-La Roche Ltd
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationF. Hoffmann-La Roche Ltd
    B.5.2Functional name of contact pointTrial Information Support Line-TISL
    B.5.3 Address:
    B.5.3.1Street AddressGrenzacherstrasse 124
    B.5.3.2Town/ cityBasilea
    B.5.3.3Post code4070
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number000000
    B.5.5Fax number000000
    B.5.6E-mailglobal.rochegenentechtrials@roche.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/14/1328
    D.3 Description of the IMP
    D.3.1Product nameidasanutlin
    D.3.2Product code RO5503781/F13-01
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNidasanutlin
    D.3.9.1CAS number 1229705-06-9
    D.3.9.2Current sponsor codeRO5503781
    D.3.9.4EV Substance CodeSUB167603
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name CITARABINA HOSPIRA - 1 G/10 ML SOLUZIONE INIETTABILE 1 FLACONCINO DA 10 ML
    D.2.1.1.2Name of the Marketing Authorisation holderHOSPIRA ITALIA S.R.L.
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCitarabina
    D.3.2Product code [NA]
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCYTARABINA
    D.3.9.1CAS number 147-94-4
    D.3.9.2Current sponsor codeNA
    D.3.9.4EV Substance CodeSUB06880MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsed or refractory acute myeloid leukemia (AML)
    LEUCEMIA MIELOIDE ACUTA RECIDIVATA O REFRATTARIA (LMA)
    E.1.1.1Medical condition in easily understood language
    Acute myeloid leukemia (AML) is a type of cancer that starts in the blood-forming cells of the bone marrow, characterised by an overproduction of immature white blood cells.
    La Leucemia Mieloide Acuta (LMA ) ¿ un tipo di cancro che inizia nella cellule ematopoietiche del midollo osseo, caratterizzate da una sovrapproduzione di globuli bianchi immaturi.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level LLT
    E.1.2Classification code 10000886
    E.1.2Term Acute myeloid leukemia
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Within the TP53 wild-type population:
    - To compare overall survival (OS) in patients with relapsed or refractory AML who have been randomized to idasanutlin in combination with cytarabine versus those who have been randomized to cytarabine and placebo.
    Nella popolazione con TP53 wild-type
    ¿ Confrontare la sopravvivenza globale (OS, Overall Survival) in pazienti affetti da leucemia mieloide acuta (LMA) recidivata o refrattaria che sono stati randomizzati a ricevere idasanutlin in associazione a citarabina rispetto a quelli randomizzati a ricevere citarabina e placebo.
    E.2.2Secondary objectives of the trial
    Within the TP53 wild-type population
    - To compare the proportions of complete remission (CR) and allogeneic hematopoietic stem cell transplant (HSCT) following CR between treatment arms
    - To compare ORR (CR, complete remission with incomplete platelet count recovery (CRp), CR with incomplete blood count recovery (CRi)), event-free survival (EFS), and duration of remission (DoR) between
    treatment arms
    - To assess OS and CR in clinically actionable mutation-defined AML subpopulations, including FLT3, IDH1, and IDH2
    - To assess the safety of idasanutlin plus cytarabine as compared with cytarabine and placebo
    - To compare the differences in disease and treatment-related symptoms and health related quality of life (HRQoL) between treatment arms.

    Within the all-patient population
    - To assess the safety between treatment arms
    - To characterize the pharmacokinetics of both idasanutlin and cytarabine
    - To compare the differences in disease and treatment related symptoms and HRQoL.
    Popolazione di paz. con TP53 WT
    •Confrontare le % di CR (CompleteRemission) e di HSCT (HematopoieticStemCellTransplant) in seguito a CR
    •Confrontare ORR (OverallRemissionRate-definito come CR), CRp (CompleteRem. with incompl. platelet count recovery), Cri (Complete Rem. with incompl. blood count recovery), EFS (Event-FreeSurvival), DOR (DurationOfRem.followingCR)
    •Valutare OS e CR nelle sottopop. affette da LMA definita da mutazioni clinicam. azionabili, comprese mutaz. di FLT3, IDH1 e IDH2
    •Valutare la sicurezza di idasanutlin+citarabina vs citarabina e placebo
    •Confrontare le diff. in termini di sintomi correlati alla malattia e al trattam. e in termini di qualità della vita correlata alla salute
    Popolazione di paz. complessiva
    •Valutare la sicurezza tra bracci di trattam.
    •Caratterizzare la farmacoc. di idasanutlin e citarabina.
    •Confrontare le diff. in termini di sintomi della malattia e al trattam. e in termini di qualità della vita correlata alla salute tra bracci di trattam.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Age >=18 years
    - Documented/confirmed 1st/2nd refractory/relapsed AML using World Health Organization classification, except acute promyelocytic leukemia
    - No more than 2 prior induction regimens (excl. prior HSCT) in their 1st line treatment and one
    must have included cytarabine with an anthracycline (or
    anthracenedione)
    - Eastern Cooperative Oncology Group performance status of 0 to 1
    - Adequate hepatic and renal function.
    - WBC count at randomization of <=50,000/cubic millimeter (mm3).
    - Età ³ 18 anni.
    - Diagnosi documentata/confermata di LMA alla prima/seconda recidiva o refrattaria, utilizzando la classificazione dell’Organizzazione Mondiale della Sanità, eccetto leucemia promielocitica acuta
    - Non più di 2 precedenti regimi di induzione (escluso precedente HSCT), di cui uno deve aver incluso citarabina con un'antraciclina (o un antracenedione).
    - Punteggio del performance status secondo l'Eastern Cooperative Oncology Group (ECOG) compreso tra 0 e 1.
    - Funzione epatica adeguata
    - Conta totale dei globuli bianchi (WBC) al momento della randomizzazione = 50.000 / mm3
    E.4Principal exclusion criteria
    - First relapsed patients aged < 60 years with a CR1 duration of > 1 year
    - AML secondary to any prior chemotherapy unrelated to leukemia
    - Patients who are either refractory to/or relapsed within 90 days of receiving a regimen containing a cumulative dose of >=18 gram/square meter cytarabine
    - Patients who hace received allogeneic HSCT within 90 days prior to randomization
    - Patients who have received immunosoppresive therapy for graft versus host disease within 2 weeks prior to randomization
    - Prior tratment with a Murine Double Minute 2 (MDM2) antagonist
    - Patients with clinically relevant QTc prolongation (QTcF > 480 ms), a family history of long QT syndrome, or who are currently receiving treatment with medications that are known to prolong the QT interval
    - Patients receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy within 30 days from the first receipt of study drug with the exception of HU or leukapheresis in patients who need to continue this therapy to maintain a WBC count <=50000/mm3. HU or leukapheresis must be discontinued at least 24 hours prior to the initiation of study medication
    - Patients with acute toxicities from any prior anti-leukemia therapy that have not resolved to Grade <=2 per National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE), version 4.03
    - Patients with a history of other malignancy within 5 years prior to screening
    - Patients unable to temporarily interrupt treatment with moderate to strng CYP2C8inducers and inhibitors (including gemfibrozil, which is also an inhibitor of UGT1A3), CYP2C8 or OATP1B1/3 substrates, or strong CYP3A4 inducers during the treatment phase. These agents must be discontinued 7-14 days prior to the start of study medication
    - Patients unable to temporarily interrupt treatment with oral or parenteral anticoagulants/anti-platelet agents (e.g., warfarin, chronic daily treatment with aspirin [>325 mg/day], clopidogrel, dabigatran, apixaban, rivaroxaban, or subcutaneous [SC] anticoagulant prophylaxis) during the tratment phase. These agents must be discontinued 7 days (or 5 half-lives) prior to the start of the study medication
    - Patients with a history of systemic hypersensitivity reactions >=Grade 2 attibuted to cytarabine
    - Patients who have any severe and/or uncontrolled medical conditions or other conditions that could impair the ability of the investigator to evaluate the patient, or impair the patient's ability to complete the study
    - Infection considered by the investigator to be clinically uncontrolled or of unacceptable risk to the patient upon the induction of neutropenia, that is, patients who are or should be on antimicrobial agents for the treatment of active infection
    - Patients with extramedullary AML with no evidence of systemic involvement
    - Pazienti in prima ricaduta con CR1 di durata > 1 anno ED età < 60 anni.
    - LMA secondaria a qualsiasi precedente chemioterapia non correlata alla leucemia.
    - Pazienti refrattari a o pazienti che hanno sviluppato una recidiva entro 90 giorni da un regime contenente una dose cumulativa di citarabina >=18g/m2
    - Pazienti sottoposti ad HSCT allogenico nei 90 giorni precedenti la randomizzazione
    - Pazienti sottoposti a terapia immunosoppressiva per malattia da trapianto contro l’ospite (graft versus host disease) nelle 2 settimane prima della randomizzazione
    - Precedente trattamento con un antagonista di MDM2.
    - Pazienti con prolungamento del QTc clinicamente rilevante (intervallo QT corretto utilizzando la formula di Fridericia [QTcF]>480ms), con anamnesi familiare di sindrome da allungamento del QT op azienti che stanno ricevendo un trattamento con farmaci noti per prolungare l'Intervallo QT.
    - Pazienti trattati con agenti sperimentali o commerciali o terapie somministrate con l’intento di trattare la neoplasia nei 30 giorni (o 5 emivite) precedenti la prima somministrazione del farmaco in studio, eccetto idrossiurea (HU) in pazienti che necessitano di proseguire l'assunzione di tale agente per mantenere una conta leucocitaria <= 50.000/mm3. La HU o la leucaferesi devono essere interrotte almeno 24 ore prima dellinizio del trattamento in studio.
    - Pazienti con tossicità acute derivanti da qualsiasi precedente terapia anti-leucemica che non siano state ricondotte ad un grado <=2 secondo i Common Terminology Criteria for Adverse Events del National Cancer Institute (NCI CTCAE), Versione 4.03.
    - Pazienti con anamnesi di altra neoplasia maligna nei 5 anni precedenti lo screening.
    - Pazienti che durante la fase di trattamento dello studio non possono temporaneamente interrompere il trattamento con moderati o forti induttori e inibitori del CYP2C8 (inclusi gemfibrozil, che è anche un inibitore UGT1A3), substrati di CYP2C8 o OATP1B1/3, oppure forti induttori del CYP3A4. Questi agenti devono essere interrotti almeno 7-14 giorni prima dell'inizio del trattamento in studio.
    - Pazienti che durante la fase di trattamento dello studio non possono interrompere temporaneamente la terapia orlae o parenterale con agenti anticoagulanti/antiaggreganti piastrinici (ad esempio warfarin, trattamento cronico quotidiano con aspirina [>325 mg/die], clopidogrel, dabigatran, apixaban, rivaroxaban o profilassi anticoagulante per via sottocutanea [SC]. Questi farmaci devono essere interrotti almeno 7 giorni (o 5 emivite) prima dell'inizio del trattamento in studio.
    - Pazienti con una storia di ipersensibilità sistemica di grado >=2 attribuite alla citarabina
    - Pazienti che presentano patologie gravi e/o non adeguatamente controllate, o altre condizioni che potrebbero influire sulla loro partecipazione allo studio, compromettere la possibilità da parte dello sperimentatore di valutare il paziente o compromettere la possibilità di completare lo studio
    E.5 End points
    E.5.1Primary end point(s)
    Overall survival (OS) in TP53 wild-type population.
    La sopravvivenza globale ( OS) inella popolazione TP53 wild-type
    E.5.1.1Timepoint(s) of evaluation of this end point
    - Interim analysis, after 120 patients enrolled
    - Primary analysis, approximately 4.5 years after study start.
    - Analisi ad Interim, dopo arruolamento di 120 pazienti
    - Analisi primaria, approssimativamente 4.5 anni dopo l'inizio dello studio
    E.5.2Secondary end point(s)
    In TP53 wild-type population
    - CR proportions
    - ORR (CR, CRp and CRi)
    - EFS
    - DOR
    - Proportion of HSCT
    - OS and CR in clinically actionable mutation-defined AML subpopulations, incl. FLT3, IDH1, and IDH2
    - Safety, disease and treatment related symptoms, and health related quality of life (HRQoL).

    Within the all-patient population
    - Safety, pharmacokinetics, disease and treatment related symptoms, and HRQoL.
    Popolazione di paz. con TP53 WT
    • Percentuale di CR.
    • EFS.
    • ORR (CR, CRp e CRi).
    • DOR (durata della remissione a seguito di CR).
    • Percentuale di HSCT a seguito di CR.
    • Percentuale di CR e OS nella sottopopolazione definita da mutazioni clinicamente azionabili (FLT3, IDH1 e IDH2).
    • Sicuezza, sintomi correlati alla malattia e al trattam. e qualità della vita correlata alla salute
    Popolazione di paz. complessiva
    • Sicuezza, Farmacocinetica, sintomi correlati alla malattia e al trattam. e qualità della vita correlata alla salute
    E.5.2.1Timepoint(s) of evaluation of this end point
    - Futility interim analysis, after 120 patients enrolled; Efficacy interim analysis at 80% of OS events (TP53 wild-type)
    - Primary analysis, approximately 5.5 years after study start.
    - Analisi ad Interim di futilità, dopo arruolamento di 120 pazienti; Analisi ad interim di efficacia all'80% degli eventi OS (TP53 WT)
    - Analisi primaria, approssimativamente 5.5 anni dopo l'inizio dello studio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned17
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA56
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Israel
    Korea, Republic of
    New Zealand
    Russian Federation
    Taiwan
    Austria
    Belgium
    Finland
    France
    Germany
    Italy
    Netherlands
    Norway
    Spain
    Switzerland
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months1
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 176
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 264
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state120
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 338
    F.4.2.2In the whole clinical trial 440
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-12-29
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-01-13
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Apr 30 04:11:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA